Kazem Kazempour

1.0k total citations
11 papers, 399 citations indexed

About

Kazem Kazempour is a scholar working on Infectious Diseases, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Kazem Kazempour has authored 11 papers receiving a total of 399 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Infectious Diseases, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Epidemiology. Recurrent topics in Kazem Kazempour's work include Menopause: Health Impacts and Treatments (3 papers), HIV Research and Treatment (2 papers) and HIV/AIDS Research and Interventions (2 papers). Kazem Kazempour is often cited by papers focused on Menopause: Health Impacts and Treatments (3 papers), HIV Research and Treatment (2 papers) and HIV/AIDS Research and Interventions (2 papers). Kazem Kazempour collaborates with scholars based in United States, Netherlands and Canada. Kazem Kazempour's co-authors include Joel Lippman, Andrew M. Kaunitz, David Portman, Gregory M. Glenn, James A. Simon, David C. Flyer, Robin McKenzie, Sarah A. Frech, A. Louis Bourgeois and Christa Schorr and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Kazem Kazempour

11 papers receiving 383 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kazem Kazempour United States	9	136	99	94	91	74	11	399
Candan Tunçer Türkiye	13	14 0.1×	128 1.3×	111 1.2×	131 1.4×	89 1.2×	29	539
C. L. Jones Australia	11	44 0.3×	54 0.5×	35 0.4×	77 0.8×	9 0.1×	20	401
Marie‐Charlotte Hallouin France	10	121 0.9×	148 1.5×	25 0.3×	92 1.0×	46 0.6×	13	563
Tercan Us Türkiye	10	16 0.1×	59 0.6×	19 0.2×	109 1.2×	20 0.3×	33	300
David Elphick United Kingdom	11	16 0.1×	20 0.2×	60 0.6×	94 1.0×	42 0.6×	20	523
Donato Amodio Italy	12	25 0.2×	110 1.1×	45 0.5×	160 1.8×	8 0.1×	39	471
C. Alexander United States	8	56 0.4×	57 0.6×	56 0.6×	45 0.5×	36 0.5×	19	496
Kelly Hodgson Australia	6	38 0.3×	191 1.9×	64 0.7×	185 2.0×	4 0.1×	6	458
Michael de Vera United States	11	25 0.2×	128 1.3×	13 0.1×	198 2.2×	19 0.3×	19	683
Sunday Pam Nigeria	13	15 0.1×	45 0.5×	31 0.3×	66 0.7×	62 0.8×	48	586

Countries citing papers authored by Kazem Kazempour

Since Specialization

Citations

This map shows the geographic impact of Kazem Kazempour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kazem Kazempour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kazem Kazempour more than expected).

Fields of papers citing papers by Kazem Kazempour

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kazem Kazempour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kazem Kazempour. The network helps show where Kazem Kazempour may publish in the future.

Co-authorship network of co-authors of Kazem Kazempour

This figure shows the co-authorship network connecting the top 25 collaborators of Kazem Kazempour. A scholar is included among the top collaborators of Kazem Kazempour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kazem Kazempour. Kazem Kazempour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Cristofanilli, Massimo, Marek Doležal, Jay Lalezari, et al.. (2020). Abstract CT233: Phase Ib/II study of leronlimab (PRO 140) combined with carboplatin in CCR5+ mTNBC patients. Cancer Research. 80(16_Supplement). CT233–CT233. 6 indexed citations

Dhody, Kush, et al.. (2018). PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection. HIV Clinical Trials. 19(3). 85–93. 34 indexed citations

Leuck, Anne‐Marie, James R. Johnson, Matthew A. Hunt, et al.. (2015). Safety and efficacy of a novel silver-impregnated urinary catheter system for preventing catheter-associated bacteriuria: A pilot randomized clinical trial. American Journal of Infection Control. 43(3). 260–265. 21 indexed citations

Klein, David J., Debra Foster, Christa Schorr, et al.. (2014). The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial. Trials. 15(1). 218–218. 71 indexed citations

Portman, David, et al.. (2014). Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause. Menopause The Journal of The North American Menopause Society. 21(10). 1082–1090. 21 indexed citations

Pinkerton, JoAnn V., et al.. (2014). Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause. Menopause The Journal of The North American Menopause Society. 22(1). 50–58. 33 indexed citations

Simon, James A., et al.. (2013). Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms. Menopause The Journal of The North American Menopause Society. 20(10). 1027–1035. 92 indexed citations

McKenzie, Robin, A. Louis Bourgeois, Sarah A. Frech, et al.. (2007). Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): Protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine. 25(18). 3684–3691. 93 indexed citations

Marshall, John L., James Posey, Simran Malik, et al.. (2007). A phase I trial of RX-0201 (AKT anti-sense) in patients with an advanced cancer. Journal of Clinical Oncology. 25(18_suppl). 3564–3564. 11 indexed citations

10.

Hastings, Kenneth L., et al.. (1998). Inhibition of Tumor Necrosis Factor Alpha Alters Resistance toMycobacterium aviumComplex Infection in Mice. Antimicrobial Agents and Chemotherapy. 42(9). 2336–2341. 14 indexed citations

11.

Kazempour, Kazem, et al.. (1995). Survival effects of ZDV, ddI, and ddC in patients with CD4 < or = 50 cells/mm3.. PubMed. 10 Suppl 2. S97–106. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact